Falini B, Canino S, Sacchi S, Ciani C, Martelli M F, Gerdes J, Stein H, Pileri S, Gobbi M, Fagioli M
Department of Clinical Medicine, Perugia University, Italy.
Br J Haematol. 1988 Jul;69(3):311-20. doi: 10.1111/j.1365-2141.1988.tb02368.x.
The monoclonal antibody Ki-67, directed against a nuclear antigen expressed by dividing cells in all the phases of cell cycle except G0 and early G1, was used in combination with an anti-BrdU monoclonal antibody, reacting selectively with cells in S-phase, for assessing the percentage of proliferating cells in bone marrow and peripheral blood samples from patients with lymphoma, leukaemia and multiple myeloma. Immunocytochemical labelling of proliferating cells was performed on marrow frozen sections and/or cytospins using an immunoalkaline phosphatase (APAAP) technique that made it possible to obtain proliferative index measurements in a few hours in contrast to the 3-7 d needed with tritiated thymidine. In the 54 marrow lymphoma cases studied a highly significant correlation was observed between the proportion of Ki-67 (+) cells and the separation into low- and high-grade malignant lymphomas according to the Kiel classification. In patients with multiple myeloma at the first diagnosis, the percentage of Ki-67 (+) cells was low (6-10%). In contrast, a high percentage of Ki-67 (+) cells (40-50%) was observed in a young adult with multiple myeloma, in a patient who first presented at the clinical observation with an extradural mass and in three patients who developed extramedullary masses several years after the initial diagnosis of myeloma. In acute lymphoblastic leukaemias of common type the mean value of Ki-67 labelling was 31.3%. Because of their simplicity and rapidity, immunocytochemical techniques may be expected to replace autoradiography and flow cytometry for the detection of proliferating cells in haematological samples.
单克隆抗体Ki-67可针对除G0期和G1早期外细胞周期所有阶段的分裂细胞所表达的一种核抗原,它与一种抗BrdU单克隆抗体联合使用,后者可选择性地与S期细胞发生反应,用于评估淋巴瘤、白血病和多发性骨髓瘤患者骨髓和外周血样本中增殖细胞的百分比。使用免疫碱性磷酸酶(APAAP)技术对骨髓冰冻切片和/或细胞涂片进行增殖细胞的免疫细胞化学标记,与使用氚标记胸腺嘧啶所需的3 - 7天相比,该技术能够在数小时内获得增殖指数测量结果。在所研究的54例骨髓淋巴瘤病例中,根据Kiel分类法,Ki-67(+)细胞比例与低级别和高级别恶性淋巴瘤的区分之间存在高度显著的相关性。在初诊的多发性骨髓瘤患者中,Ki-67(+)细胞的百分比很低(6 - 10%)。相比之下,在一名患有多发性骨髓瘤的年轻成人、一名首次临床观察时表现为硬膜外肿块的患者以及三名在骨髓瘤初诊数年之后出现髓外肿块的患者中,观察到Ki-67(+)细胞的高百分比(40 - 50%)。在常见类型的急性淋巴细胞白血病中,Ki-67标记的平均值为31.3%。由于免疫细胞化学技术简单快速,有望取代放射自显影和流式细胞术用于检测血液学样本中的增殖细胞。